Top-Rated StocksTop-RatedNASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis → See this before next week's Fed meeting (From Stansberry Research) (Ad) Free FDMT Stock Alerts $23.80 -0.45 (-1.86%) (As of 11:19 AM ET) Add Compare Share Share Today's Range$22.91▼$23.9350-Day Range$24.25▼$35.8752-Week Range$9.44▼$36.25Volume116,523 shsAverage Volume1.04 million shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/APrice Target$44.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 4D Molecular Therapeutics alerts: Email Address 4D Molecular Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.3% Upside$44.22 Price TargetShort InterestBearish18.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.90Based on 7 Articles This WeekInsider TradingSelling Shares$4.07 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.03) to ($3.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector379th out of 907 stocksBiological Products, Except Diagnostic Industry54th out of 153 stocks 4.5 Analyst's Opinion Consensus Rating4D Molecular Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coverage4D Molecular Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.22% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FDMT. Previous Next 2.7 News and Social Media Coverage News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for 4D Molecular Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,074,435.00 in company stock.Percentage Held by Insiders10.70% of the stock of 4D Molecular Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($3.03) to ($3.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchSee this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it. About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Read More FDMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FDMT Stock News HeadlinesApril 20, 2024 | insidertrades.comScott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockApril 19, 2024 | insidertrades.comInsider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of StockApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) April 4, 2024 | insidertrades.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $259,102.34 in StockMarch 31, 2024 | insidertrades.comScott Bizily Sells 5,833 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockApril 21, 2024 | investing.com4d Molecular Therapeutics exec sells $45k in stockApril 17, 2024 | msn.com4D Molecular Therapeutics (FDMT) Price Target Increased by 5.81% to 53.24April 17, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst UpgradeApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) April 17, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading 2.5% Higher After Analyst UpgradeApril 16, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Receives New Coverage from Analysts at BarclaysApril 16, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Increased to $40.00 by Analysts at Royal Bank of CanadaApril 15, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)April 12, 2024 | investing.com4D Molecular Therapeutics Inc (FDMT)April 4, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 SharesMarch 29, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company SharesMarch 29, 2024 | markets.businessinsider.comOptimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710March 28, 2024 | globenewswire.com4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisMarch 4, 2024 | globenewswire.com4DMT to Participate in Upcoming Investor ConferencesMarch 2, 2024 | finance.yahoo.com4D Molecular Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 2, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc Reports Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.com4DMT Reports Full Year 2023 Financial Results and Operational HighlightsFebruary 24, 2024 | msn.com4D Molecular Therapeutics (FDMT) Price Target Increased by 47.68% to 50.55February 23, 2024 | benzinga.com4D Molecular Therapeutics Stock (NASDAQ:FDMT) Dividends: History, Yield and DatesFebruary 13, 2024 | markets.businessinsider.comBuy Rating on 4D Molecular Therapeutics Backed by Strong Clinical Results and Broad Commercial ProspectsFebruary 12, 2024 | finance.yahoo.comInstitutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growthFebruary 12, 2024 | finance.yahoo.com4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024See More Headlines Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FDMT CUSIPN/A CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees147Year FoundedN/APrice Target and Rating Average Stock Price Target$44.22 High Stock Price Target$81.00 Low Stock Price Target$24.00 Potential Upside/Downside+82.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,840,000.00 Net Margins-436.30% Pretax Margin-486.60% Return on Equity-34.14% Return on Assets-31.07% Debt Debt-to-Equity RatioN/A Current Ratio15.65 Quick Ratio15.65 Sales & Book Value Annual Sales$20.72 million Price / Sales59.88 Cash FlowN/A Price / Cash FlowN/A Book Value$7.20 per share Price / Book3.37Miscellaneous Outstanding Shares51,160,000Free Float45,683,000Market Cap$1.24 billion OptionableOptionable Beta2.87 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. John F. Milligan Ph.D. (Age 63)Executive Chairman Comp: $150kDr. David H. Kirn M.D. (Age 62)Co-Founder, CEO & Director Comp: $920.97kDr. Fariborz Kamal Ph.D. (Age 61)President & COO Comp: $678.4kDr. Noriyuki Kasahara M.D. (Age 61)Ph.D., Chief Scientific Officer Comp: $13.6kMs. Theresa Janke (Age 49)Co-Founder & Chief of Staff Comp: $652.32kMr. Uneek Mehra (Age 52)Chief Financial & Business Officer Dr. Scott P. Bizily J.D. (Age 51)Ph.D., Chief Legal Officer & Corporate Secretary Dr. Robert Y. Kim M.B.A. (Age 63)M.D., Chief Medical Officer Dr. An Song Ph.D.Chief Development OfficerDr. Alan H. Cohen FAAAAI (Age 63)FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology More ExecutivesKey CompetitorsAutolus TherapeuticsNASDAQ:AUTLTarsus PharmaceuticalsNASDAQ:TARSScholar RockNASDAQ:SRRKAdaptimmune TherapeuticsNASDAQ:ADAPVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 430,556 shares on 4/24/2024Ownership: 0.842%Allspring Global Investments Holdings LLCBought 3,026 shares on 4/18/2024Ownership: 0.007%Scott BizilySold 1,750 sharesTotal: $45,045.00 ($25.74/share)Scott BizilySold 8,153 sharesTotal: $259,102.34 ($31.78/share)Scott BizilySold 5,833 sharesTotal: $204,388.32 ($35.04/share)View All Insider TransactionsView All Institutional Transactions FDMT Stock Analysis - Frequently Asked Questions Should I buy or sell 4D Molecular Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FDMT shares. View FDMT analyst ratings or view top-rated stocks. What is 4D Molecular Therapeutics' stock price target for 2024? 10 equities research analysts have issued 12-month price objectives for 4D Molecular Therapeutics' shares. Their FDMT share price targets range from $24.00 to $81.00. On average, they anticipate the company's stock price to reach $44.22 in the next twelve months. This suggests a possible upside of 91.3% from the stock's current price. View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts. How have FDMT shares performed in 2024? 4D Molecular Therapeutics' stock was trading at $20.26 on January 1st, 2024. Since then, FDMT stock has increased by 14.1% and is now trading at $23.12. View the best growth stocks for 2024 here. Are investors shorting 4D Molecular Therapeutics? 4D Molecular Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,320,000 shares, an increase of 9.6% from the March 15th total of 8,500,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is currently 8.0 days. View 4D Molecular Therapeutics' Short Interest. When is 4D Molecular Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FDMT earnings forecast. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.09. The firm had revenue of ($0.02) million for the quarter, compared to the consensus estimate of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative trailing twelve-month return on equity of 34.14%. What ETFs hold 4D Molecular Therapeutics' stock? ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Genomics Immunology and Healthcare ETF (IDNA).ALPS Medical Breakthroughs ETF (SBIO). When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? 4D Molecular Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.84%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko, Robert Young Kim and Scott Bizily. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FDMT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWill this $2 AI stock double overnight?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
